Back to journals
Academic Journal

British Journal of Psychiatry

10 Papers Indexed in Blossom

Published Papers

Open Accessindividual

MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study

In an open‑label proof‑of‑principle study of 12 participants with moderate–severe major depressive disorder, two MDMA‑assisted therapy sessions plus psychotherapy were feasible, well tolerated and produced large, statistically significant reductions in depressive symptoms (mean MADRS change −19.3) and functional impairment. No unexpected or serious adverse events occurred, and the authors conclude that randomised trials are needed to confirm efficacy.

Published
Journal
British Journal of Psychiatry
Authors
Kvam, T. M., Goksøyr, I. W., Rog, J., Jentoft Van De Vooren, I. T., Stewart, H., Autran, I., Berthold-Losleben, M., Mørch-Johnsen, L., Holst, R., Clausen, I., Andreassen, O. A.
Open Accessindividual

Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study

In this secondary analysis of a multisite, double-blind RCT (n=174) in treatment‑resistant depression, subcutaneous racemic ketamine given twice weekly for 4 weeks at flexible, response‑guided doses (35-63mg/70kg) produced a significant short‑term reduction in anxiety (HAM‑A) versus midazolam, whereas a fixed low dose (35mg/70kg) did not. The anxiolytic effect was mediated by antidepressant response and was not maintained 4 weeks after the end of treatment.

Published
Journal
British Journal of Psychiatry
Authors
Mills, N. T., Nikolin, S., Glozier, N., Barton, D., Baune, B. T., Fitzgerald, P. B., Glue, P., Sarma, S., Rodgers, A., Hadzi-Pavlovic, D., Alonzo, A., Dong, V., Martin, D., Mitchell, P. B., Berk, M., Carter, G., Hackett, L., Somogyi, A. A., Mihalopoulos, C., Chatterton, M. L., Hood, S., Loo, C. K.
Open Accessindividual

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial

Sensitivity analyses of the randomised ESCAPE‑TRD trial confirmed that adjunctive esketamine nasal spray was consistently superior to quetiapine extended release for achieving remission at Week 8 and remaining relapse‑free to Week 32 (relative risks 1.46–1.84, all p<0.05). Esketamine also shortened time to first and confirmed remission (hazard ratios ≈1.66–1.71), supporting the robustness of the original findings.

Published
Journal
British Journal of Psychiatry
Authors
Young, A. H., Llorca, P. M., Fagiolini, A., Falkai, P., Cardoner, N., Nielsen, R. E., Blomqvist, O., Godinov, Y., Rive, B., Diels, J., Mulhern-Haughey, S., Reif, A.
Open Accessindividual

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

In this phase 3 randomised double‑blind trial, adequately dosed subcutaneous racemic ketamine given twice weekly for 4 weeks produced significantly higher remission than midazolam in the flexible‑dose cohort (19.6% v. 2.0%; OR 12.1, 95% CI 2.1–69.2, P = 0.005) but not in the fixed‑dose cohort. Ketamine was well tolerated with transient adverse effects resolving within two hours, supporting the subcutaneous route as a practical option for treatment‑resistant depression.

Published
Journal
British Journal of Psychiatry
Authors
Loo, C., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P., Glue, P., Sarma, S., Galvez-Ortiz, V., Hadzi-Pavlovic, D., Alonzo, A., Dong, V., Martin, D., Nikolin, S., Mitchell, P. B., Berk, M., Carter, G., Hackett, M., Leyden, J., Hood, S., Somogyi, A. A., Lapidus, K., Stratton, E., Gainsford, K., Garg, D., Thornton, N. L. R., Fourrier, C., Richardson, K., Rozakis, D., Scaria, A., Mihalopoulos, C., Chatterton, M. L., McDonald, W. M., Boyce, P., Holtzheimer, P. E., Kozel, F. A., Riva-Posse, P., Rodgers, A.
Open Accessmeta

Can psychedelic compounds play a part in drug dependence therapy?

The paper reviews renewed interest in psychedelic-assisted therapies for drug dependence, summarising emerging studies of psilocybin, ketamine, ibogaine and ayahuasca. Despite clinical and legal limitations, it argues that the potential to improve patient outcomes warrants further research.

Published
Journal
British Journal of Psychiatry
Authors
Sessa, B., Johnson, M. W.
Open Accessmeta

Can psychedelics have a role in psychiatry once again?

The paper reviews the natural abundance and millennia‑long human use of psychedelics (LSD, mescaline, psilocybin, MDMA, DMT) and argues they warrant renewed consideration for therapeutic applications in psychiatry.

Published
Journal
British Journal of Psychiatry
Authors
Sessa, B.

Quick Facts

Papers Indexed
10
h-Index
264
Open Access
No
Publisher
Cambridge University Press
Country
United Kingdom
Website
Visit